Chronic pain of osteoarthritis: Considerations for selecting an extended-release opioid analgesic

American Journal of Therapeutics

Volumn 15, Issue 3, 2008, Pages 241-255

  Gibofsky, Allan ^a,b   Barkin, Robert L ^c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d North Shore Pain Center   (United States)

Author keywords

Analgesic; Chronic pain; Extended release; Opioids; Osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CODEINE; DEXTROPROPOXYPHENE NAPSILATE; DICLOFENAC; FENOPROFEN; FENTANYL; FLURBIPROFEN; HYDROMORPHONE; INDOMETACIN; KETOPROFEN; KETOROLAC; LEVORPHANOL; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; METHADONE; MORPHINE SULFATE; NABUMETONE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPANA; OXAPROZIN; OXYCODONE; OXYMORPHONE; PARACETAMOL; PIROXICAM; SALSALATE; SULINDAC; TOLMETIN; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ANALGESIA; BLEEDING; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMPETITIVE INHIBITION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; FLUID RETENTION; FLUSHING; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERKALEMIA; INSOMNIA; KIDNEY DYSFUNCTION; KNEE PAIN; LIVER TOXICITY; MALE SEXUAL DYSFUNCTION; MYOCLONUS; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SOMNOLENCE; URINE RETENTION; VOMITING; XEROSTOMIA; CHRONIC DISEASE; DELAYED RELEASE FORMULATION; OPIATE ADDICTION; PAIN;

ANALGESICS, OPIOID; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; OPIOID-RELATED DISORDERS; OSTEOARTHRITIS; PAIN;

EID: 45949106973     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181727f68     Document Type: Review

References (104)

1. Peter D. Hart Research Associates: Americans talk about pain. A survey among adults nationwide conducted for Research America [website]. 2003. Available at: http://www.researchamerica.org/polldata/2003/painpoll03.pdf. Accessed July 25, 2007.
2. Brookoff D. Chronic pain: 1. A new disease? Hosp Pract (Minneap). 2000;35:45-52, 59.
3. Watkins JC, Jane DE. The glutamate story. Br J Pharmacol. 2006;147 (Suppl 1) :S100-S108.
4. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175: 265-275.
5. Dellemijn P. Are opioids effective in relieving neuropathic pain? Pain. 1999;80:453-462.
6. Rowbotham MC. Efficacy of opioids in neuropathic pain. In: Hansson PT, Fields HL, Hill RG, et al, eds. Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management. Seattle, WA: IASP Press; 2001:203-213.
7. Jordan JM, Bernard SL, Callahan LF, et al. Self-reported arthritis-related disruptions in sleep and daily life and the use of medical, complementary, and self-care strategies for arthritis: the National Survey of Self-Care and Aging. Arch Fam Med. 2000;9:143-149.
8. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskelet al. disorders in the United States. Arthritis Rheum. 1998;41: 778-799.
9. National Institutes of Health, National Institute of Arthritis and Musculoskelet al. and Skin Diseases (NIAMS). Osteoarthritis. Handout on Health. NIH Publication No. 06-4617. NIAMS/National Institutes of Health, Bethesda, MD: 2002.
10. Gelber AC, Hochberg MC, Mead LA, et al. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000;133:321-328.
11. Roos EM. Joint injury causes knee osteoarthritis in young adults. Curr Opin Rheumatol. 2005;17:195-200.
12. Ricci JA, Stewart WF, Chee E, et al. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum. 2005;53:673-681.
13. Jakobsson U, Hallberg IR. Quality of life among older adults with osteoarthritis: an explorative study. J Gerontol Nurs. 2006;32:51-60.
14. Salaffi F, Carotti M, Stancati A, et al. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res. 2005;17:255-263.
15. Barkin RL. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007;14:299-305.
16. Wilcox S, Brenes GA, Levine D, et al. Factors related to sleep disturbance in older adults experiencing knee pain or knee pain with radiographic evidence of knee osteoarthritis. J Am Geriatr Soc. 2000;48:1241-1251.
17. Leigh TJ, Hindmarch I, Bird HA, et al. Comparison of sleep in osteoarthritic patients and age and sex matched healthy controls. Ann Rheum Dis. 1988;47:40-42.
18. Crichton B, Green M. GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis. Curr Med Res Opin. 2002;18:92-96.
19. Mowers RM, Cheema GS. Treatment options for osteoarthritis: scientific review [website]. 2004. Available at: http://www.chcf.org/documents/ chronicdisease /OsteoarthritisTreatmentOptions.pdf. Accessed October 19, 2006.
20. Yee A. Part VII: Formulary. In: Paget SA, Beary JFI, Gibofsky A, et al, eds. Manual of Rheumatology and Outpatient Orthopedic Disorders: Diagnosis and Therapy. Philadelphia, PA: Lippincott Williams and Wilkins; 2006: 497-556.
21. Wickersham RM. Facts and Comparisons 4.0 [website]. 2007. Available at: http://www.factsandcomparisons.com/Products/index.aspx?cat=8&id=1112. Accessed July 25, 2007.
22. Ortho-McNeil Pharmaceutical Inc, assignee. TYLENOL® with codeine (acetaminophen and codeine phosphate) tablets [package insert]. 2004.
23. Purdue Pharma L. P, assignee. OXY CONTIN® (oxycodone HCl controlled-release) tablets [package insert]. 2005.
24. aaiPharma LLC, assignee. DARVON-N® propoxyphene tablets [package insert]. 2004. @25. King Pharmaceuticals Inc, assignee. AVINZA® (morphine sulfate extended-release capsules) [package insert]. 2006.
25. Purdue Pharma L. P, assignee. MS-CONTIN® (morphine sulfate controlled-release) tablets [package insert]. 2005.
26. aaiPharma Inc, assignee. ORAMORPH® SR tablets [package insert]. 2005.
27. aaiPharma Inc, assignee. ROXANOL® ROXANOL-T® morphine sulfate (immediate release) oral solution (concentrate) [package insert]. 2004.
28. Endo Pharmaceuticals Inc, assignee. OPANA® ER (oxymorphone hydrochloride) extended-release tablets [package insert]. 2006.
29. Janssen Pharmaceutica Products, L. P, assignee. DURA GESIC® (fentanyl transdermal system) [package insert]. 2005.
30. Knoll Laboratories, assignee. DILAUDID® (hydromorphone HCl) [package insert]. 2005.
31. Roxane Laboratories Inc, assignee. DOLOPHINE® hydrochloride [package insert]. 2000.
32. Mallinckrodt Inc, assignee. METHADOSE® oral tablets [package insert]. 2002.
33. Valeant Pharmaceuticals International, assignee. LEVO- DROMORAN® [package insert]. 2005.
34. Ortho-McNeil Pharmaceutical Inc, assignee. ULTRAM® (tramadol hydrochloride tablets) [package insert]. 2004.
35. PriCara™ a unit of Ortho-McNeil Inc, assignee. ULTRAM® ER (tramadol HCl) Extended-Release Tablets [package insert]. 2006.
36. Towheed TE, Maxwell L. Acetaminophen for osteoarthritis [review]. Cochrane Database Syst Rev. 2006: CD004257.
37. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657-662.
38. Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy. 2007;27:675-683.
39. Groarke JF, Averett JM, Hirschowitz BI. Acetaminophen and hepatic necrosis. N Engl J Med. 1977;296:233-233.
40. Katz WA. Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. Curr Opin Rheumatol. 2002;14:63-71.
41. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
42. Hungin AP, Kean WF. Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis? Am J Med. 2001;110:8S-11S.
43. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997; 49:15-19.
44. Singh G. Recent considerations in nonsteroidal antiinflammatory drug gastropathy. Am J Med. 1998;105: 31S-38S.
45. Cryer B. Gastrointestinal Effects of NSAIDs and COX-2 Specific Inhibitors. FDA Arthritis Advisory Committee. Available at www.fda.gov/ohrms/dockets/ac/05 /transcripts/2005-409T1.htm. Accessed July 26, 2007.
46. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095-1105.
47. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med. 2000;160:1781-1787.
48. Buvanendran A, Barkin R. Lumiracoxib. Drugs Today (Barc). 2007;43:137-147.
49. Andersohn F, Suissa S, Garbe E. Use of first- and secondgeneration cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113:1950-1957.
50. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132-140.
51. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.
52. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081-1091.
53. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
54. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
55. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790-804.
56. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;111:64-67.
57. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633- 1644.
58. Fishman SM, Teichera D. Challenges and choices in drug therapy for chronic pain. Cleve Clin J Med. 2003;70: 119-138.
59. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non- NSAID analgesics. Am J Ther. 2000;7:63-74.
60. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.
61. Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs. 1996;51:713-737.
62. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181-186.
63. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther. 2002;9:53-68.
64. Barkin RL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene) : a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther. 2006;13:534-542.
65. Thompson AR, Ray JB. The importance of opioid tolerance: a therapeutic paradox. J Am Coll Surg. 2003; 196:321-324.
66. Adriaensen H, Vissers K, Noorduin H, et al. Opioid tolerance and dependence: an inevitable consequence of chronic treatment? Acta Anaesthesiol Belg. 2003;54: 37-47.
67. Morley-Forster PK, Clark AJ, Speechley M, et al. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag. 2003;8:189-194.
68. Raffa RB, Nayak RK, Liao S, et al. The mechanism (s) of action and pharmacokinetics of tramadol hydrochloride. Rev Contemp Pharmacother. 1995;6:485-497.
69. Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf. 2005;14:851-859.
70. Bourne MH, Rosenthal NR, Xiang J, et al. Tramadol /acetaminophen tablets in the treatment of postsurgical orthopedic pain. Am J Orthop. 2005;34:592-597.
71. Fricke JR Jr, Hewitt DJ, Jordan DM, et al. A doubleblind placebo-controlled comparison of tramadol /acetaminophen and tramadol in patients with postoperative dental pain. Pain. 2004;109:250-257.
72. Smith AB, Ravikumar TS, Kamin M, et al. Combination tramadol plus acetaminophen for postsurgical pain. Am J Surg. 2004;187:521-527.
73. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm. 1997;54:643-652.
74. Barkin RL. Focus on tramadol: a centrally acting analgesic for moderately severe pain. Formulary. 1995; 30:321-325.
75. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879-923.
76. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992;260: 275-285.
77. Emkey R, Rosenthal N, Wu SC, et al. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004;31:150-156.
78. Schug SA. Combination analgesia in 2005-a rational approach: focus on paracetamol-tramadol. Clin Rheumatol. 2006;25 (Suppl 1) :S16-S21.
79. Katz WA. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs. 1996;52 (Suppl 3) :39-47.
80. Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology. 1982;56:93-96.
81. Barkin RL, Barkin D. Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J. 2001;94:756-770.
82. Barkin RL, Iusco AM, Barkin SJ. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In: Cole BE, Boswell MV, eds. Weiner's Pain Management: A Practical Guide for Clinicians. Boca Raton, FL: CRC Press; 2006:779-794.
83. Alpharma Pharmaceuticals LLC, assignee. KADIAN® (morphine sulfate extended-release) capsules [package insert]. 2007.
84. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. JPain Symptom Manage. 2002;23:278-291.
85. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and activecontrolled phase III trial. Pain Med. 2005;6:357-366.
86. Kivitz A, Ma C, Ahdieh H, et al. A 2-week, multicenter, randomized, double-blind, placebo-controlled, doseranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther. 2006;28:352-364.
87. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther. 2005;12:106-112.
88. Markenson JA, Croft J, Zhang PG, et al. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005;21:524-535.
89. Roth SH, Fleischmann RM, Burch FX, et al. Aroundthe-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000;160:853-860.
90. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26:862-869.
91. Langford R, McKenna F, Ratcliffe S, et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1829-1837.
92. Pavelka K, Le Loet X, Bjorneboe O, et al. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Curr Med Res Opin. 2004;20:1967-1977.
93. Eradiri O, Sista S, Lai JC-K, et al. Bioavailability of extended-release and immediate-release formulations of tramadol HCl. J Clin Pharmacol. 2006;46:1091. Abstract 126.
94. Barkin RL. Extended-release Tramadol (ULTRAM ®ER) : A pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther. 2008;15: 157-166.
95. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28:59-71.
96. Gana TJ, Pascual MLG, Fleming RRB, et al. Extendedrelease tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebocontrolled clinical trial. Curr Med Res Opin. 2006;22: 1391-1401.
97. Janagap C, Schein J, Kosinski M, et al. Quality-of-life outcomes of tramadol HCl extended-release tablet (ULTRAM ER) in patients with osteoarthritis. Paper presented at: The 70th Annual Meeting of the American College of Rheumatology; November 10-15, 2006; Washington, DC.
98. Vorsanger G, Jordan D, Xiang J, et al. Effect of extendedrelease tramadol on pain in the elderly. Presented at: The 17th Annual Clinical Meeting of the American Academy of Pain Management; September 7-10, 2006; Orlando, FL. 100. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 1999;42:1370-1377.
99. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
100. Murthy B, Danyluk A, Skee D, et al. Dose conversion of immediate- to extended-release tramadol using a population pharmacokinetic approach. J Clin Pharmacol. 2006;46:1091. Abstract 124.
101. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv. 2006;3:489-497.
102. Klotz U. Tramadol-the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung. 2003;53:681-687.
103. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6:662-672.
104. Adams EH, Breiner S, Cicero TJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006;31:465-476.